MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-21-2026
XTL Biopharmaceuticals Ltd. DSO Ratio 2011-2026 | XTLB
Annual DSO Ratio XTL Biopharmaceuticals Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 65.6 | 49 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 65.6 | 49 | 57.3 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
115 | $ 20.36 | -1.64 % | $ 2.57 B | USA |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.81 | -3.83 % | $ 4.42 M | China |
 |
Axsome Therapeutics
AXSM
|
105 | $ 164.62 | -1.06 % | $ 8.19 B | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Certara
CERT
|
89.6 | $ 7.27 | 3.05 % | $ 1.17 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
59.5 | $ 23.94 | 0.23 % | $ 2.93 B | USA |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Eton Pharmaceuticals
ETON
|
30.4 | $ 17.89 | -1.43 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
43.4 | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
31.9 | $ 26.27 | -2.2 % | $ 703 M | USA |
 |
Galapagos NV
GLPG
|
56.5 | $ 33.2 | -2.61 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
97.9 | $ 27.76 | -6.37 % | $ 17.6 B |  Danmark |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
32.9 | $ 1.0 | -1.47 % | $ 73.4 M | USA |
 |
Halozyme Therapeutics
HALO
|
93.4 | $ 69.4 | -0.64 % | $ 8.32 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
Harmony Biosciences Holdings
HRMY
|
37.8 | $ 28.63 | -0.95 % | $ 1.65 B | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
41 | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Immuron Limited
IMRN
|
148 | $ 0.75 | -0.69 % | $ 6.46 M |  Australia |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
4.13 | $ 3.24 | -3.14 % | $ 1.16 M | USA |
 |
Inhibrx
INBX
|
31.1 | $ 76.35 | -1.47 % | $ 3.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
InMed Pharmaceuticals
INM
|
3.83 | $ 0.78 | -4.88 % | $ 1.91 M | Canada |
 |
INmune Bio
INMB
|
60.1 K | $ 1.39 | 4.66 % | $ 25 M | USA |
 |
Insmed Incorporated
INSM
|
58 | $ 147.23 | 0.62 % | $ 29.3 B | USA |